TABLE 3.
Summary of results obtained for MRSE isolates from Iceland
| PFGE type; no. (%) of isolatesa | PFGE subtype (no. of isolates) | Antibiotype (>50%)b,c | Clinical datad
|
||
|---|---|---|---|---|---|
| Source(s) | Infection or colonization | ||||
| C; 23 (24.5) | C1 (11) | CIP, GEN, OXA, SXT, TET | Bl, W | I, C | |
| C2 (4) | |||||
| C5 (3) | |||||
| C8 (1) | |||||
| C9 (1) | |||||
| C10 (2) | |||||
| C11 (1) | |||||
| B; 12 (12.8) | B3 (9) | GEN, OXA, SXT | Bl, W | I, C | |
| B4 (3) | |||||
| A; 9 (9.6) | A11 (2) | CHL, GEN, OXA, SXT | U, Bl, W, R | I, C | |
| A12 (2) | |||||
| A13 (1) | |||||
| A14 (1) | |||||
| A15 (1) | |||||
| A16 (1) | |||||
| A17 (1) | |||||
| G; 8 (8.5) | G1 (2) | CLI, ERY, GEN, OXA, RIF, SXT | I, C | ||
| G3 (2) | |||||
| G4 (1) | |||||
| G5 (2) | |||||
| G6 (1) | |||||
| D; 7 (7.4) | D1 (3) | CHL, ERY, GEN, OXA, SXT | U, W, Bl | I, C | |
| D4 (1) | |||||
| D5 (1) | |||||
| D6 (1) | |||||
| D7 (1) | |||||
| EE; 6 (6.4) | EE1 (6) | CLI, ERY, GEN, OXA, RIF, SXT | Bl, W | I, C | |
| FF; 4 (4.3) | FF1 (1) | OXA, SXT | W | I, C | |
| FF2 (1) | |||||
| FF3 (1) | |||||
| FF4 (1) | |||||
| I; 3 (3.2) | I1 (3) | CIP, OXA | Bl, W | C | |
| BB; 2 (2.1) | BB1 (2) | OXA, SXT, TEC, TET | Bl, W | C | |
| GG; 2 (2.1) | GG1 (2) | CIP, CLI, ERY, GEN, OXA, RIF, SXT | U, W | I, C | |
| HH; 2 (2.1) | HH1 (1) | CHL, CLI, ERY, GEN, OXA, SXT, TEC, TET | W | C | |
| HH2 (1) | |||||
| II; 2 (2.1) | II1 (1) | CLI, ERY, OXA, SXT, TET | U, W | I | |
| II2 (1) | |||||
| F; 1 (1.1) | F3 (1) | OXA, SXT | W | C | |
| H; 1 (1.1) | H3 (1) | CLI, ERY, OXA, SXT | W | C | |
| K; 1 (1.1) | K2 (1) | CHL, CLI, ERY, GEN, OXA | W | I | |
| N; 1 (1.1) | N3 (1) | CLI, ERY, OXA | R | C | |
| Q; 1 (1.1) | Q1 (1) | GEN, OXA, RIF, SXT | B | I | |
| V; 1 (1.1) | V2 (1) | ERY, GEN, OXA, SXT | B | C | |
| S; 1 (1.1) | S1 (1) | CIP, ERY, GEN, OXA, SXT, TEC, TET | U, W | I, C | |
| DD; 1 (1.1) | DD1 (1) | CLI, ERY, GEN, OXA, RIF, SXT | W | I | |
| KK; 1 (1.1) | KK1 (1) | CHL, CIP, CLI, ERY, GEN, OXA, SXT | Bl | I | |
| LL; 1 (1.1) | LL1 (1) | OXA | Bl | C | |
| MM; 1 (1.1) | MM1 (1) | OXA | W | C | |
| OO; 1 (1.1) | OO1 (1) | ERY, GEN, OXA | Bl | C | |
| PP; 1 (1.1) | PP1 (1) | CIP, CLI, ERY, GEN, OXA, SXT, TET | U | I | |
| QQ; 1 (1.1) | QQ1 (1) | CIP, CLI, ERY, GEN, OXA, SXT | U | I | |
a
Numbers in parentheses correspond to the frequency of each PFGE type in relation to the total number of MRSE isolates in Iceland.
b
Antibiogram for more than 50% of isolates with this PFGE type.
c
CHL, chloramphenicol; CIP, ciprofloxacin; CLI, clindamycin; ERY, erythromycin; GEN, gentamicin; OXA, oxacillin; RIF, rifampin; TEC, teicoplanin; TET, tetracycline; SXT, trimethoprim-sulfamethoxazole.
d
Bl, blood; C, colonization; I, infection; ot, other sources; R, respiratory tract; W, wound; U, urine.